New Products

SARS-CoV-2 Neutralizing Antibody ELISA Kit

With the demand for vaccine development, Creative Diagnostics have developed two ELISA kits for qualitative detection of SARS-CoV-2 neutralizing antibody in serum and plasma.

Product Lists:

Cat. No. Product Name Coating
DEIASL055 SARS-CoV-2 Neutralizing Antibody Assay Kit  hACE2
DEIA-WZ021 SARS-CoV-2 Neutralizing Antibody Assay Kit  RBD

Kits Features

  • The detection of SARS-CoV-2 neutralizing antibodies offers important information for evaluating immune responses to COVID-19. It has multiple applications such as studies of human immunity and vaccine development among others.
  • CD’ SARS-CoV-2 Neutralizing Antibody ELISA Kit functions as a simple, qualitative indicator of positive or negative samples. Disease-free positive and negative plasma controls are supplied to confirm the assay is performing as expected.
  • The format of our ELISA (in which neutralizing antibodies must recognize the SARS-CoV-2 spike receptor binding domain to inhibit ACE2 binding) provides an efficient and effective screening tool for determining functional antibody neutralization capabilities.
  • The entire detection process takes about 80 minutes, while traditional neutralization experiments require cell culture, which usually takes 2-3 days to complete the test.
  • Since a sterile environment is not required, the detection operation can be performed under general experimental conditions, which is more convenient.

Antigens and Antibodies for COVID-19 Neutralizing Antibody Assays

Humanized SARS-CoV-2 Neutralizing Antibody
CABT-CS033 SARS-CoV-2 S1 Monoclonal antibody, clone BIB114 (Humanized)

Assay Formats

Our competitive assay format measures neutralizing antibodies of the SARS-CoV-2 spike RBD and ACE2 interaction in human plasma and serum. For DEIASL055, recombinant human ACE2 receptor protein is immobilized on the plate, followed by the addition of neutralizing antibody or HRP labelled RBD. This interaction is then detected by reading absorbance at 450 nm. The interaction between SARS-CoV-2 spike RBD and ACE2 is disrupted in the presence of neutralizing antibodies in the sample, preventing signal emission (Figure 1). For DEIA-WZ021, recombinant RBD protein is immobilized on the plate instead of human ACE2 and HRP labelled recombinant human ACE2 is added into the plate to competitive with neutralizing antibody (Figure 2). This assay format allows for the detection of all neutralizing antibodies independent of isotype, including IgA, which is particularly salient to mucosal tissue infections.

Figure 1. Assay Principle of Creative Diagnostics SARS-CoV-2 Neutralizing Antibody ELISA Kit (CD Cat# DEIASL055)Figure 1. Assay Principle of Creative Diagnostics SARS-CoV-2 Neutralizing Antibody ELISA Kit (CD Cat# DEIASL055)

Figure 2. Assay Principle of Creative Diagnostics SARS-CoV-2 Neutralizing Antibody ELISA Kit (CD Cat# DEIA-WZ021)Figure 2. Assay Principle of Creative Diagnostics SARS-CoV-2 Neutralizing Antibody ELISA Kit (CD Cat# DEIA-WZ021)


Since the outbreak of the new coronavirus pneumonia (Corona Virus Disease 2019, COVID-19), it has rapidly swept across most countries around the world and is still spreading. To deal with the epidemic, it is very urgent to successfully develop a safe and effective vaccine. According to the data released by the WHO a few days ago, there are 198 candidate new coronavirus vaccines being developed and registered in various countries, of which 44 have entered the clinical trial stage, and 10 have entered the phase III clinical trial. In the process of vaccine development and marketing, the presence of neutralizing antibodies can indicate an ability to suppress progression of SARS-CoV-2 infection and is important in evaluating the lifetime and efficacy of specific antibodies in the host.

Figure 3. Neutralizing Antibody blocking S protein<br />
from binding to ACE2 Receptor.Figure 3. Neutralizing Antibody blocking S protein
from binding to ACE2 Receptor.

The SARS-CoV-2 surface glycoprotein, also known as the spike glycoprotein, is located on the outer envelope of the virion and contains the receptor binding domain (RBD), which binds to angiotensin-converting enzyme 2 (ACE2), the functional receptor for SARS-CoV-2. SARS-CoV-2 infection can result in the production of neutralizing antibodies, which bind to the SARS-CoV-2 spike RBD preventing further viral entry and infection, starting approximately 4-10 days after symptom onset (Figure 3). The detection of neutralizing antibodies can provide valuable information for researchers studying immune responses or human immunity to SARS-CoV-2, as well as for the development of effective vaccines.

Related Products:

SARS-CoV-2 Neutralizing Antibodies


  1. Shi, Rui, et al. "A human neutralizing antibody targets the receptor binding site of SARS-CoV-2." Nature 584.7819(2020):1-8.
  2. Zost, S.J., Gilchuk, P., Case, J.B. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449 (2020).
  3. Jiang, Shibo, C. Hillyer, and L. Du. "Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses." Trends in Immunology 41.5(2020).
  4. Lu, Roujian, et al. "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding." The Lancet 395.10224(2020).
  5. A, F. A. Klok, et al. "Incidence of thrombotic complications in critically ill ICU patients with COVID-19 - ScienceDirect." Thrombosis Research 191(2020):145-147.
  6. Shang, Jian, et al. "Cell entry mechanisms of SARS-CoV-2." Proceedings of the National Academy of Sciences 117.21(2020):202003138.
  7. "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation." Science 367.
Inquiry Basket